USUBJID,BOR,BORDT,BORCONF,BORN,DERIVATION_NOTES
001-001,PR,2024-05-07,Y,2,PR confirmed: -60% at Week 16 with 56-day confirmation from Week 8
001-002,CR,2024-05-12,Y,1,CR confirmed: Complete disappearance maintained at 56-day confirmation
001-003,PD,2024-03-29,N,4,Early PD: +33% increase meets progression criteria at Week 8
001-004,PR,2024-05-28,Y,2,PR at threshold: Exactly -30% confirmed at 56 days
001-005,SD,2024-06-02,Y,3,Below PR threshold: -29.9% does not meet -30% requirement
001-006,SD,2024-06-07,Y,3,Insufficient absolute increase: +20% but only +4mm (requires â‰¥5mm)
001-007,PD,2024-06-12,Y,4,PD confirmed: +20.5% and +4.1mm meets both criteria
001-008,CR,2024-06-17,Y,1,CR confirmed: Complete response maintained at 56 days
001-009,PR,2024-05-26,N,2,PR unconfirmed: Day 85 exceeds 84-day maximum confirmation window
001-010,PR,2024-05-29,Y,2,PR confirmed: Day 84 is at maximum boundary of confirmation window
001-011,PR,2024-07-30,N,2,PR unconfirmed: Day 142 far exceeds confirmation window maximum
001-012,PR,2024-06-08,Y,2,PR confirmed: -37.5% with 42-day confirmation meets minimum SD duration
001-013,CR,2024-07-11,Y,1,Overall CR: Target CR + Non-target absent per RECIST Table 4
001-014,PR,2024-07-16,Y,2,Overall PR: Target PR + Non-target stable (non-CR/non-PD)
001-015,PD,2024-05-27,Y,4,Overall PD: Non-target progression overrides target PR response
001-016,CR,2024-07-27,Y,1,Overall CR: Target CR + Non-target absent throughout
001-017,PD,2024-08-01,N,4,New lesion PD: Target CR negated by new lesion detection
001-018,CR,2024-08-06,Y,1,Equivocal new lesion: Resolved as false positive at Week 24
001-019,PD,2024-06-16,N,4,Multiple new lesions: Automatic PD with target and brain metastases
001-020,PR,2024-06-21,N,2,Missing data: Week 16 assessment missing prevents confirmation
001-021,PR,2024-06-27,N,2,Early withdrawal: Patient discontinued before confirmation visit
001-022,PD,2024-07-01,Y,4,Initial PD: +21% and +20mm at Week 8 meets progression criteria
001-023,PD,2024-07-06,N,4,Response after PD: Week 16 improvement does not override initial PD
001-024,PR,2024-08-08,Y,2,SD minimum duration: 28-day confirmation at minimum acceptable interval
001-025,SD,2024-09-10,Y,3,Stable disease: -25% reduction insufficient for PR (-30% required)